Important Safety Information on Yescarta (axicabtagene ciloleucel) and the Risk of Cerebral Edema in Primary Mediastinal B Cell Lymphoma (PMBCL)
Critical priority
The issue
New safety information
Affected product
Yescarta (axicabtagene ciloleucel) Suspension for Intravenous Infusion
Where it was sold
ONReported in the official notice — confirm there.
Issued by
Health Canada — Marketed health products
Read the official Government of Canada notice
All recallsRecallGuardian ranks, illustrates and rewrites recalls in plain language. The official notice is authoritative — confirm model numbers, lot codes, dates and remedies there.